A Phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors

Isambert N (1), Hollebecque A (2), Berge Y (3), van Ingen H (4), Brienza S (4), Destaillats A(4), Soria JC (2), Fumoleau P(1), Delord JP (3)

Poster presented at ASCO Annual Meeting 2012 in Chicago, USA

1. Centre Georges-François Leclerc, Dijon, France
2. Institut Gustave Roussy, Villejuif, France
3. Institut Claudius Regaud, Toulouse, France
4. Debiopharm SA, Lausanne, Switzerland